Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by LEMS, W. F.
Right arrow Articles by BIJLSMA, J. W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEMS, W. F.
Right arrow Articles by BIJLSMA, J. W. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

research-article

TRANSIENT DECREASE IN OSTEOCALCIN AND MARKERS OF TYPE 1 COLLAGEN TURNOVER DURING HIGH-DOSE CORTICOSTEROID PULSE THERAPY IN RHEUMATOID ARTHRITIS

W. F. LEMS, J. W. G. JACOBS, H. R. VAN DEN BRINK, H. J. M. VAN RIJN and J. W. J. BIJLSMA

Department of Rheumatology F02.223. University Hospital Utrechi PO Box 85500, 3508 GA Utrechi, The Netherlands

The effect of corticosteroid pulse therapy on bone metabolism was studied in 10 patients with active RA. We measured alkaline phosphatase, osteocalcin and two recently introduced markers of collagen type 1 metabolism, reflecting synthesis (PICP) and degradation (ICTP).

The day after the pulse therapy, there was a statistically significant (P<0.05) decrease in osteocalcin, PICP and ICTP from the value at start. Three weeks after pulse therapy, these values had returned to baseline.

During pulse treatment there is a transient decrease in bone formation, as shown by the changes in osteocalcin and PICP. Because of the changes in ICTP, we conclude that bone resorption is transiently reduced as well, but whether these changes result from a direct or an indirect effect on bone is not clear. ICTP has to be investigated further as a (serum) marker of bone resorption.

KEY WORDS: Corticosteroids, Bone metabolism, Osteocalcin, Rheumatoid arthritis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
F Buttgereit, G Burmester, J W Bijlsma, P Durez, A Nzeusseu Toukap, B R Lauwerys, D H Manicourt, J-P Devogelaer, F A Houssiau, P Verschueren, et al.
Which dose regimen for glucocorticoid pulse therapy in patients with severe refractory RA? * Authors' reply
Ann Rheum Dis, January 1, 2005; 64(1): 171 - 172.
[Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
P C Ng, C W K Lam, G W K Wong, C H Lee, P S Cheng, T F Fok, I H S Chan, E Wong, K Cheung, and S Y Lee
Changes in markers of bone metabolism during dexamethasone treatment for chronic lung disease in preterm infants
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2002; 86(1): F49 - 54.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.